KR101689847B1 - 디플루프레드네이트를 포함하는 황반부종 치료용 점안액 - Google Patents

디플루프레드네이트를 포함하는 황반부종 치료용 점안액 Download PDF

Info

Publication number
KR101689847B1
KR101689847B1 KR1020117012096A KR20117012096A KR101689847B1 KR 101689847 B1 KR101689847 B1 KR 101689847B1 KR 1020117012096 A KR1020117012096 A KR 1020117012096A KR 20117012096 A KR20117012096 A KR 20117012096A KR 101689847 B1 KR101689847 B1 KR 101689847B1
Authority
KR
South Korea
Prior art keywords
delete delete
administration
weeks
day
eye drops
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117012096A
Other languages
English (en)
Korean (ko)
Other versions
KR20120040683A (ko
Inventor
히데토시 야마시타
데이코 야마모토
사키코 고토
사치 아베
에리코 기리
아츠시 오쿠무라
Original Assignee
야마가타 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야마가타 유니버시티 filed Critical 야마가타 유니버시티
Publication of KR20120040683A publication Critical patent/KR20120040683A/ko
Application granted granted Critical
Publication of KR101689847B1 publication Critical patent/KR101689847B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020117012096A 2009-07-14 2010-07-14 디플루프레드네이트를 포함하는 황반부종 치료용 점안액 Expired - Fee Related KR101689847B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2009-165924 2009-07-14
JP2009165924 2009-07-14
PCT/JP2010/062289 WO2011007893A1 (en) 2009-07-14 2010-07-14 Eye drop with difluprednate for macular edema treatment

Publications (2)

Publication Number Publication Date
KR20120040683A KR20120040683A (ko) 2012-04-27
KR101689847B1 true KR101689847B1 (ko) 2016-12-26

Family

ID=42646370

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117012096A Expired - Fee Related KR101689847B1 (ko) 2009-07-14 2010-07-14 디플루프레드네이트를 포함하는 황반부종 치료용 점안액

Country Status (13)

Country Link
US (3) US20110190250A1 (enExample)
EP (1) EP2340014B1 (enExample)
JP (1) JP5579079B2 (enExample)
KR (1) KR101689847B1 (enExample)
CN (3) CN102170865A (enExample)
BR (1) BRPI1005380A2 (enExample)
CA (1) CA2738151C (enExample)
ES (1) ES2405779T3 (enExample)
MX (1) MX2011005043A (enExample)
PL (1) PL2340014T3 (enExample)
RU (1) RU2572707C2 (enExample)
TW (1) TW201105363A (enExample)
WO (1) WO2011007893A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210012346A (ko) 2019-07-25 2021-02-03 심낙범 미세먼지 눈꺼풀 세정스틱

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5902100B2 (ja) * 2011-01-14 2016-04-13 株式会社エス・ディー・エス バイオテック ４−（３−ブチニル）アミノピリミジン誘導体を含む農園芸用有害生物防除剤組成物
US20140018402A1 (en) * 2011-03-30 2014-01-16 Catholic University Industry Academic Cooperation Foundation Pharmaceutical composition for preventing or treating macular degeneration
CN103130857A (zh) * 2011-11-30 2013-06-05 天津金耀集团有限公司 二氟泼尼酯ⅱ晶型及其制备方法
CN103130859B (zh) * 2011-11-30 2015-12-02 天津金耀集团有限公司 二氟泼尼酯晶型i及其制备方法
KR20150119315A (ko) * 2013-02-15 2015-10-23 센주 세이야꾸 가부시키가이샤 아연을 함유하는 디플루프레드네이트 유액 조성물
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
WO2015197594A2 (de) 2014-06-23 2015-12-30 Schott Ag Elektrisches speichersystem enthaltend ein scheibenförmiges diskretes element, scheibenförmiges diskretes element sowie verfahren zu dessen herstellung und dessen verwendung
JP2018505515A (ja) 2014-12-01 2018-02-22 ショット アクチエンゲゼルシャフトＳｃｈｏｔｔ ＡＧ シート状の独立した部材を有する蓄電システム、独立したシート状の部材、その製造方法、およびその使用
EP4566638A3 (en) * 2015-05-29 2025-08-27 Allergan, Inc. Implant for treatment of an ocular condition
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
CN108014172A (zh) * 2017-12-29 2018-05-11 广州仁恒医药科技股份有限公司 一种含有二氟泼尼酯的药物组合物及其制备方法
US20210100856A1 (en) * 2019-09-11 2021-04-08 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
WO2021050649A1 (en) * 2019-09-11 2021-03-18 Adverum Biotechnologies, Inc. Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099717A1 (en) * 2004-04-13 2005-10-27 Bausch & Lomb Incorporated Macular edema patient selection method and treatment with eye implant comprising a steroid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3781792B2 (ja) 1993-12-27 2006-05-31 千寿製薬株式会社 ジフルプレドナート含有点眼用懸濁液剤
AU684115B2 (en) 1993-12-27 1997-12-04 Mitsubishi Chemical Corporation Ophthalmic suspension containing diflupredonate
US6114319A (en) 1997-05-14 2000-09-05 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
JP3410364B2 (ja) 1997-05-14 2003-05-26 千寿製薬株式会社 ジフルプレドナート含有組成物
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
MXPA05008561A (es) * 2003-02-20 2005-11-04 Alcon Inc Uso de esteroides para tratar personas que sufren de trastornos oculares.
US20060009498A1 (en) * 2004-07-12 2006-01-12 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
US20070049568A1 (en) 2005-08-25 2007-03-01 Psivida Inc. Control of induced elevated intraocular pressure
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099717A1 (en) * 2004-04-13 2005-10-27 Bausch & Lomb Incorporated Macular edema patient selection method and treatment with eye implant comprising a steroid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210012346A (ko) 2019-07-25 2021-02-03 심낙범 미세먼지 눈꺼풀 세정스틱

Also Published As

Publication number Publication date
ES2405779T3 (es) 2013-06-03
US20110190250A1 (en) 2011-08-04
EP2340014B1 (en) 2013-04-24
KR20120040683A (ko) 2012-04-27
CN103705524A (zh) 2014-04-09
CN102170865A (zh) 2011-08-31
RU2011125640A (ru) 2013-08-20
CN107569494A (zh) 2018-01-12
EP2340014A1 (en) 2011-07-06
CA2738151C (en) 2017-02-28
US20180133153A1 (en) 2018-05-17
US9949926B2 (en) 2018-04-24
WO2011007893A1 (en) 2011-01-20
JP2012533517A (ja) 2012-12-27
PL2340014T3 (pl) 2013-09-30
RU2572707C2 (ru) 2016-01-20
BRPI1005380A2 (pt) 2016-02-10
US10092514B2 (en) 2018-10-09
US20150190340A1 (en) 2015-07-09
MX2011005043A (es) 2011-06-01
TW201105363A (en) 2011-02-16
JP5579079B2 (ja) 2014-08-27
CA2738151A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
KR101689847B1 (ko) 디플루프레드네이트를 포함하는 황반부종 치료용 점안액
JP2017061467A5 (enExample)
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
US8404270B2 (en) Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids
JP2005535691A (ja) 加齢性黄斑変性を有する患者における視力の保護のための酢酸アネコルタブの使用
Watanabe et al. Efficacy of intravitreal triamcinolone acetonide for diabetic macular edema after vitrectomy
Hanif et al. Safety and efficacy of suprachoroidal injection of triamcinolone in treating macular edema secondary to noninfectious uveitis
Sandoval et al. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution versus 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation
KR20050102653A (ko) 병적 눈 혈관신생 치료용 글루코코르티코이드 제제
US20070043006A1 (en) Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
CN100353947C (zh) 以甾体为有效成分的视网膜和脉络膜疾病治疗剂
Ellakwa et al. Evaluation of nepafenac eye drops in prevention of macular edema following cataract surgery
Gama Pseudophakic macular edema (irvine-gass syndrome): has the treatment changed?
Kurz et al. Injectable intraocular corticosteroids
Amer et al. Role of corneal collagen cross-linkage in the treatment of keratoconus
ZA200509532B (en) Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
JP2007056012A (ja) 軟膏様組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191221

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191221